Tiotropium respimat inhaler and the risk of death in COPD

New England Journal of Medicine

Volumn 369, Issue 16, 2013, Pages 1491-1501

  Wise, Robert A ^a   Anzueto, Antonio ^b   Cotton, Daniel ^d   Dahl, Ronald ^e   Devins, Theresa ^d   Disse, Bernd ^f   Dusser, Daniel ^g   Joseph, Elizabeth ^d   Kattenbeck, Sabine ^f   Koenen Bergmann, Michael ^f   Pledger, Gordon ^c   Calverley, Peter ^h  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Boehringer Ingelheim Pharmaceuticals ^*

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^g University of Liverpool ^*  (France)

^h UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TIOTROPIUM BROMIDE;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CARDIOVASCULAR EFFECT; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DEVICE SAFETY; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; FEMALE; FOLLOW UP; HAZARD RATIO; HEART INFARCTION; HUMAN; INHALER; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; RISK ASSESSMENT; RISK OF DEATH; SPIROMETRY; TRANSIENT ISCHEMIC ATTACK;

EID: 84885734407     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1303342     Document Type: Article

References (26)

1. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364:1093-103.
2. Bateman ED, Tashkin D, Siafakas N, et al. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir Med 2010;104:1460-72.
3. Cooper CB, Celli BR, Jardim JR, et al. Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial. Chest 2013;144:490-7.
4. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
5. Boehringer Ingelheim. Summary of Product Characteristics (SPC): Spiriva 18 microgram inhalation powder, hard capsule. eMC, 2012 (http://www.medicines. org.uk/emc/medicine/10039/SPC/ Spiriva+18microgram+inhalation+powder%2c+hard+capsule).
6. Idem. Summary of Product Characteristics (SPC): Spiriva Respimat 2.5 microgram solution for inhalation. eMC, 2013 (http://www.medicines.org.uk/emc/ medicine/20134/SPC).
7. van Noord JA, Cornelissen PJ, Aumann JL, Platz J, Mueller A, Fogarty C. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir Med 2009;103:22-9.
8. Ichinose M, Fujimoto T, Fukuchi Y. Tiotropium 5 μg via Respimat and 18 μg via HandiHaler; efficacy and safety in Japanese COPD patients. Respir Med 2010;104:228-36.
9. Boehringer Ingelheim. Tiotropium (Spiriva) Respimat: evaluation of fatal events. 2010 (http://trials.boehringer-ingelheim.com/content/dam/internet/opu/ clinicaltrial/com-EN/results/Pooled%20analysis/PA-205.372-251-252-254-255-U10- 3255-01.pdf).
10. Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011;342:d3215.
11. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;7:CD009285.
12. Dong YH, Lin HH, Shau WY, Wu YC, Chang CH, Lai MS. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 2013;68:48-56.
13. Loke YK, Singh S. Risks associated with tiotropium in chronic obstructive pulmonary disease: overview of the evidence to date. Ther Adv Drug Safe 2012;3:123-31.
14. Singh S, Loke YK, Enright P, Furberg CD. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax 2013;68:114-6.
15. Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006;61:854-62. [Erratum, Thorax 2007;62:191.]
16. Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ, Plaza Moral V, Schiavi EA. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. Respir Med 2009;103:1421-9.
17. Kesten S, Leimer I, Jara M. Risk of major adverse cardiovascular events with inhaled anticholinergics in patients with chronic obstructive pulmonary disease. JAMA 2009;301:1224-6.
18. Salpeter SR. Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events? A synthesis of the available evidence. Drugs 2009;69:2025-33.
19. Wise RA, Anzueto A, Calverley P, et al. The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale. Respir Res 2013;14:40.
20. Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:948-55.
21. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
22. Verhamme KM, Afonso A, Romio S, Stricker BC, Brusselle G, Sturkenboom M. Use of tiotropium Respimat SMI vs. tiotropium Handihaler and mortality in patients with COPD. Eur Respir J 2013 March 21 (Epub ahead of print).
23. Vestbo J, Anderson JA, Calverley PM, et al. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. Clin Respir J 2011;5:44-9.
24. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium - the FDA's conclusions. N Engl J Med 2010;363:1097-9.
25. Albert RK. "Lies, damned lies ..." and observational studies in comparative effectiveness research. Am J Respir Crit Care Med 2013;187:1173-7.
26. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010;137:20-30.